NDLI: Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.

Please wait, while we are loading the content...

Effect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity.

Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis.

Association of type 1 diabetes with two Loci on 12q13 and 16p13 and the influence coexisting thyroid autoimmunity in Japanese.

Treatment with potassium bicarbonate lowers calcium excretion and bone resorption in older men and women.

Lethal respiratory failure and mild primary hypothyroidism in a term girl with a de novo heterozygous mutation in the TITF1/NKX2.1 gene.

Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance.

Glucagon cell adenomatosis: a newly recognized disease of the endocrine pancreas.

Fertility preservation in girls with turner syndrome: prognostic signs of the presence of ovarian follicles.

Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients.

Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance.

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

Computed tomography colonography in acromegaly.

Increased glucagon-like peptide-1 secretion and postprandial hypoglycemia in children after Nissen fundoplication.

Maturation of luteinizing hormone (gonadotropin-releasing hormone) secretion across puberty: evidence for altered regulation in obese peripubertal girls.

Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Vitamin D status and its relationship to body fat, final height, and peak bone mass in young women.

Testosterone supplementation in older men restrains insulin-like growth factor's dose-dependent feedback inhibition of pulsatile growth hormone secretion.

Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus.

Hematologic effects of levothyroxine in iron-deficient subclinical hypothyroid patients: a randomized, double-blind, controlled study.

Copeptin in the differential diagnosis of hyponatremia.

Common type 2 diabetes risk gene variants associate with gestational diabetes.

Maternal thyroid disease and preterm delivery.

Epicardial adipose tissue as a source of nuclear factor-kappaB and c-Jun N-terminal kinase mediated inflammation in patients with coronary artery disease.

The TRIB3 Q84R polymorphism and risk of early-onset type 2 diabetes.

Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.

Extensive and largely reversible ischemic cerebral infarctions in a prepubertal child with hypertension and Cushing disease.

Testicular effects of isolated luteinizing hormone deficiency and reversal by long-term human chorionic gonadotropin treatment.

Polycystic ovary syndrome, inflammation, and statins: do we have the right target?

Year: 2008 Volume: 93

Year: 2007 Volume: 92

Year: 2006 Volume: 91

Year: 2005 Volume: 90

Year: 2004 Volume: 89

Year: 2003 Volume: 88

Year: 2002 Volume: 87

Year: 2001 Volume: 86

Year: 2000 Volume: 85

Year: 1999 Volume: 84

Year: 1998 Volume: 83

Year: 1972 Volume: 35

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Fuerst, Thomas Davies, Richard Y. Fitzpatrick, Lorraine A. Keaveny, Tony M. Genant, Harry K. Kopperdahl, David L. Engelke, Klaus Lewiecki, E. Michael Kivitz, Alan
Description	Country affiliation: United States Author Affiliation: Lewiecki EM ( New Mexico Clinical Research & Osteoporosis Center, 300 Oak Street NE, Albuquerque, New Mexico 87106, USA. lewiecki@aol.com)
Abstract	CONTEXT: Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone. DESIGN, SETTING, AND OBJECTIVES: This randomized, double-blind, placebo-controlled outpatient study evaluated effects of once-monthly oral ibandronate on hip and lumbar spine BMD and calculated strength using quantitative computed tomography (QCT) with finite element analysis (FEA) and dual-energy x-ray absorptiometry (DXA) with hip structural analysis (HSA). PARTICIPANTS: Participants were women aged 55-80 yr with BMD T-scores -2.0 or less to -5.0 or greater (n = 93). INTERVENTION: Oral ibandronate 150 mg/month (n = 47) or placebo (n = 46) was administered for 12 months. OUTCOME MEASURES: The primary end point was total hip QCT BMD change from baseline; secondary end points included other QCT BMD sites, FEA, DXA, areal BMD, and HSA. All analyses were exploratory, with post hoc P values. RESULTS: Ibandronate increased integral total hip QCT BMD and DXA areal BMD more than placebo at 12 months (treatment differences: 2.2%, P = 0.005; 2.0%, P = 0.003). FEA-derived hip strength to density ratio and femoral, peripheral, and trabecular strength increased with ibandronate vs. placebo (treatment differences: 4.1%, P < 0.001; 5.9%, P < 0.001; 2.5%, P = 0.011; 3.5%, P = 0.003, respectively). Ibandronate improved vertebral, peripheral, and trabecular strength and anteroposterior bending stiffness vs. placebo [7.1% (P < 0.001), 7.8% (P < 0.001), 5.6% (P = 0.023), and 6.3% (P < 0.001), respectively]. HSA-estimated femoral narrow neck cross-sectional area and moment of inertia and outer diameter increased with ibandronate vs. placebo (respectively 3.6%, P = 0.003; 4.0%, P = 0.052; 2.2%, P = 0.049). CONCLUSIONS: Once-monthly oral Ibandronate for 12 months improved hip and spine BMD measured by QCT and DXA and strength estimated by FEA of QCT scans.
ISSN	0021972X
e-ISSN	19457197
Journal	The Journal of Clinical Endocrinology & Metabolism
Issue Number	1
Volume Number	94
Language	English
Publisher	Oxford University Press
Publisher Date	2009-01-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Bone Density Conservation Agents Administration & Dosage Bone Density Drug Effects Diphosphonates Osteoporosis, Postmenopausal Drug Therapy Absorptiometry, Photon Administration, Oral Biomechanical Phenomena Bone Remodeling Double-blind Method Drug Administration Schedule Finite Element Analysis Metabolism Tomography, X-ray Computed Randomized Controlled Trial Research Support, Non-u.s. Gov't Discipline Endocrinology Discipline Metabolism
Content Type	Text
Resource Type	Article
Subject	Biochemistry (medical) Endocrinology, Diabetes and Metabolism Clinical Biochemistry Biochemistry Endocrinology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Prevention of bone loss after withdrawal of tamoxifen.

Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study.

Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.

Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.

Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.

Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.

A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.

Similar Documents

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Prevention of bone loss after withdrawal of tamoxifen.

Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study.

Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.

Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.

Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.

Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.

A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.